论文部分内容阅读
目的观察纳洛酮在治疗Ⅱ型呼吸衰竭并发肺性脑病的临床疗效。方法将76例诊断明确的Ⅱ型呼吸衰竭肺性脑病,随机分为治疗组、对照组,两组均给抗感染,持续低流量给氧,保持呼吸道通畅,维持水电解质及酸碱平稳,营氧支持,对症治疗原发疾病等综合措施。治疗组在此基础上加用纳洛酮注射剂,首次剂量为0.8mg静脉推注,以后给纳洛酮2mg静脉持续滴注,2次/d,连续三天。结果动脉血气分析指标:治疗组治疗前后动脉血气分析值比较P<0.01;对照组总有效率为70.1%,治疗组总有效率91.4%,治疗组显著高于对照组(P<0.01)。结论纳洛酮治疗Ⅱ型呼吸衰竭肺性脑病安全性较高、临床疗效显著,值得临床推广。
Objective To observe the clinical efficacy of naloxone in the treatment of respiratory failure complicated with pulmonary encephalopathy. Methods Totally 76 patients with pulmonary encephalopathy of type Ⅱ respiratory failure were randomly divided into treatment group and control group. Both groups were given anti-infection, sustained low-flow oxygenation, airway maintenance, stable water-electrolyte and acid- Oxygen support, symptomatic treatment of primary diseases and other comprehensive measures. On the basis of this, the treatment group added naloxone injection, the first dose of 0.8mg intravenous injection, after intravenous infusion of naloxone 2mg, 2 times / d, for three consecutive days. Results Arterial blood gas analysis index: The arterial blood gas analysis value in the treatment group before and after treatment was P <0.01; the total effective rate was 70.1% in the control group and 91.4% in the treatment group, which was significantly higher in the treatment group than in the control group (P <0.01). Conclusion Naloxone treatment of type Ⅱ respiratory failure of pulmonary encephalopathy higher safety, clinical efficacy is significant, worthy of clinical promotion.